EverHint – SMA20 × SMA50 Crossover Signals for Feb 05, 2026 – Healthcare Leads with 9 Setups
What This Signal Is (Quick)
This strategy detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50):
-
Buy Signal (SMA20_x_SMA50_Buy) - "Golden Cross": SMA(20) crosses above SMA(50) on today's close
- Short-term momentum (20 days) exceeds medium-term trend (50 days)
- Bullish trend confirmation with high reliability
- Ideal for medium-term trend following (4-12 week holding periods)
-
Sell Signal (SMA20_x_SMA50_Sell) - "Death Cross": SMA(20) crosses below SMA(50) on today's close
- Short-term momentum weakens below medium-term trend
- Bearish trend confirmation
- Can signal exit points or trend reversal alerts
Key Characteristics:
- Uses two SMAs (both simple moving averages) for maximum stability
- Most stable strategy - fewer signals but highest quality (fewer whipsaws)
- Better suited for medium-term trends with confirmed momentum
- Lower risk entries compared to faster EMA-based strategies
Key Criteria:
-
Buy: SMA20 crosses above SMA50
-
Sell: SMA20 crosses below SMA50
-
Minimum ADV: $40M (liquidity filter)
-
Earnings buffer: 7 days pre/post earnings
-
Fresh crossover: Detected on today's close
Holding Period: 2-6 weeks
Risk Level: Medium
How We Ranked Today
Ranked by RSI (lower RSI = more oversold for buy signals)
📊 SMA20 × SMA50 Crossover Signals (Top 15 of 38 total)
Ranked by rsi14:
| Rank | Ticker | Company | Sector | Last ($) | RSI14 | Insider Net | Days → Earnings | Est EPS | Mkt Cap ($B) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FUTU | Futu Holdings Limited | Financial Services | 149.96 | 16.7 | — | 35 | $0.00 | 20.9 |
| 2 | VRNS | Varonis Systems, Inc. | Technology | 22.21 | 17.1 | — | 88 | $0.29 | 2.6 |
| 3 | NTRA | Natera, Inc. | Healthcare | 197.08 | 17.5 | $-60.4M | 90 | $2.68 | 27.3 |
| 4 | ICLR | ICON plc | Healthcare | 145.39 | 19.1 | — | 82 | $18.02 | 11.1 |
| 5 | EA | Electronic Arts Inc. | Communication Services | 197.93 | 19.4 | $-4.7M | 88 | $15.23 | 49.5 |
| 6 | VLTO | Veralto Corp | Industrials | 90.79 | 20.2 | — | 81 | $5.13 | 22.5 |
| 7 | OMC | Omnicom Group Inc. | Communication Services | 69.12 | 22.4 | — | 67 | $14.83 | 13.3 |
| 8 | EXPE | Expedia Group, Inc. | Consumer Cyclical | 231.30 | 24.0 | — | 90 | $28.30 | 27.1 |
| 9 | XYZ | Block, Inc. | Technology | 53.38 | 25.1 | — | 83 | $6.72 | 32.5 |
| 10 | INFY | Infosys Limited | Technology | 16.80 | 27.4 | — | 69 | $0.85 | 69.8 |
| 11 | SRPT | Sarepta Therapeutics, ... | Healthcare | 17.03 | 28.3 | $-294K | 88 | $1.80 | 1.8 |
| 12 | OKLO | Oklo Inc. | Utilities | 62.14 | 29.4 | $-26.6M | 46 | $-0.26 | 9.7 |
| 13 | CIFR | Cipher Mining Inc. | Financial Services | 12.70 | 32.3 | $-3.1M | 88 | $-0.34 | 5.0 |
| 14 | TBBK | The Bancorp, Inc. | Financial Services | 58.54 | 34.1 | — | 76 | $8.03 | 2.7 |
| 15 | GLOB | Globant S.A. | Technology | 57.72 | 34.3 | — | 14 | $7.15 | 2.5 |
Field Notes
Sector concentration: Healthcare (9), Financial Services (5), Industrials (5)
Insider selling: NTRA (Natera, Inc., $-60.4M), ACLX (Arcellx, Inc., $-1.8M), EA (Electronic Arts Inc., $-4.7M)
Insider buying: MSM (MSC Industrial Direct Company,, $+2.5M)
Near-term earnings: ECG (Everus Construction Group, Inc.) report within 7 days. Higher volatility risk.
Data coverage: 23.7% insider, 5.3% congressional (1 recent/90d, 1 older/1y), 94.7% earnings, 100.0% analyst, 34.2% news
Congressional Activity
MCK (McKesson Corporation) 🔴 Bearish (1y)
- 1 sale by 1 member
- Top seller: Hou. Jonathan Jackson (IL) - 1 transaction ($1,001 - $15,000)
LLY (Eli Lilly and Company) ⚪ Neutral (90d)
- 2 total transactions: 1 purchases, 1 sales
- Top seller: Hou. David Taylor (OH) - 1 transaction ($1,001 - $15,000)
- Top buyer: Sen. Angus King (ME) - 1 transaction ($1,001 - $15,000)
Recent Headlines
CIFR (Cipher Mining Inc.)
- Cipher Mining Inc. (CIFR) Registers a Bigger Fall Than the Market: Important Facts to Note (source)
NTRA (Natera, Inc.)
- Natera Submits Signatera™ CDx PMA to FDA (source)
OKLO (Oklo Inc.)
- Better Nuclear Energy Stock: SMR vs. OKLO (source)
OMC (Omnicom Group Inc.)
- Cullen Capital Management LLC Boosts Stake in Omnicom Group Inc. $OMC (source)
- Omnicom Appoints Jantzen Bridges as Global President of its Enterprise Transformation Consultancy (source)
SRPT (Sarepta Therapeutics, Inc.)
- Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags (source)
Market Context
Broad market indices closed lower today, with the S&P 500 down 0.57%, Nasdaq declining 0.28%, and Dow Jones falling 0.68%. This uniform pullback signals waning momentum across large-cap, growth, and value segments, creating a cautious environment for trend-following strategies like SMA20/SMA50 crossovers. The VIX surged 13.15% to 21.77, indicating heightened uncertainty that amplifies intraday swings and increases the risk of false signals, as short-term moving average alignments can whipsaw in volatile conditions.
Elevated volatility challenges the reliability of SMA20/SMA50 setups, which thrive on sustained trends but falter amid choppy price action. With risk appetite appearing subdued amid the downside moves, traders may see fewer confirmed crossovers holding through session volatility, prompting tighter stops or reduced position sizes to manage drawdowns.
Sector rotation favors defensive areas like Healthcare, which generated the bulk of the 38 signals, as investors pivot from cyclical exposure in a risk-off backdrop. This implies SMA20/SMA50 opportunities could cluster in resilient sectors, offering relative strength plays, though broader market weakness may cap upside potential without a volatility retreat.
Vlad's Take (EverHint)
Today's signals: Strong sector concentration in Healthcare (9 signals) suggests sector-specific rotation. 1 signal with insider buying adds conviction. 8 signals showing insider selling warrant caution. Average RSI of 45 indicates oversold conditions.
Sharing Call-to-Action
🔍 If this breakdown was useful, feel free to like, share, or subscribe. Every bit of support matters.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/